![](images/social-icons/download.png)
Abstract
The appearance of a novel coronavirus (nCoV-2019) is a pandemic threat
which has been declared an international public health emergency. The
number of infected people went out from China to other countries has
increased since the discovery of the virus in late December 2019, and the
epidemiological picture has changed daily. The nCoV-2019 belongs to
Genera Beta coronavirus which also contains SARS and MERS i.e. (Middle
East respiratory syndrome). According to the National Institute of Health
(NIH), the first case reported in Pakistan was on 26 February 2020 and till
22 May 2020, the total number of confirmed cases in Pakistan are 52,013
with 16,012 recoveries and 1087 deaths. No medicine or vaccine for human
coronaviruses has, sadly, yet been approved. However, it can take months
to years to create new approaches. Other strategies for managing or
preventing emerging nCoV-2019 infections can be envisaged including
vaccines, monoclonal antibodies, oligonucleotide- treatment, peptides,
interferon treatment and medication with low molecular weight molecules.
In the face of the severity of the nCoV-2019 outbreak, we concentrate on
the potential for recycling existing licensed or evolving antiviral agents for
control of infections that are caused by different viruses especially influenza
viruses i.e. SARS and MERS. Therefore, it is urgently important to identify
appropriate antiviral agents to combat the outbreak of nCoV-19
Keywords: SARS, MERS, nCov-19, Prevalence, Pakistan